Arix Bioscience
plc
Autolus to present
new data at the ASH Annual Meeting
LONDON, 06 November 2019: Arix Bioscience plc
(“Arix”, LSE: ARIX), a global venture capital company focused on
investing in and building breakthrough biotech companies, today
notes that its portfolio company, Autolus Therapeutics Plc (NASDAQ:
AUTL) (“Autolus”), has announced four oral and two poster
presentations related to its AUTO1, AUTO2 and AUTO3 programmes at
the 61st American Society of Hematology (“ASH”) Annual Meeting and
Exposition, to be held December 7-10,
2019 in Orlando, FL.
The announcement can be accessed on Autolus' investor website at
https://www.autolus.com/investor-relations and full text of the
announcement from Autolus is contained below.
ENDS
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
Tel: +44 (0)20 7290 1072
charlotte@arixbioscience.com
Media Enquiries
Optimum Strategic Communications
Mary Clark/ Supriya Mathur
optimum.arix@optimumcomms.com
Tel: +44 (0) 203 950 9144
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange. For further information, please visit
www.arixbioscience.com
Autolus
Therapeutics to Present New Data on Its Advanced Programmed T Cell
Therapies at the 61st ASH Annual Meeting
-
Company to Present Four Oral Presentations and Two Posters -
LONDON, UK, November 6,
2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a
clinical-stage biopharmaceutical company developing next-generation
programmed T cell therapies for the treatment of cancer, announced
four oral and two poster presentations related to its AUTO1, AUTO2
and AUTO3 programs at the 61st American Society of Hematology (ASH)
Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando, FL.
“We are pleased that AUTO1 data will be presented in three
oral presentations at ASH. The data form the basis for our decision
to move AUTO1 into a pivotal clinical trial in adult ALL, our
highest priority program,” said Dr. Christian Itin, chairman and chief executive
officer of Autolus. “We are also looking forward to
presenting data on our other hematological clinical programs at
ASH. These presentations will further illustrate the
significant progress we have made across our clinical portfolio
this year.”
The abstracts have been published today and are available on the
ASH website at
https://www.hematology.org/Annual-Meeting/Abstracts/.
The oral presentation details are as
follows:
Title: AUTO1 – A novel fast off CD19CAR delivers
durable remissions and prolonged CAR T cell persistence with low
CRS or neurotoxicity in adult ALL
Presenter: Dr Claire Roddie
Session Date and Time: Saturday,
December 7, 2:45 PM Eastern
Time
Title: AUTO1 – Therapy of pediatric
B-ALL with a lower affinity CD19 CAR leads to enhanced expansion
and prolonged CAR T cell persistence in patients with low bone
marrow tumor burden, and is associated with a favorable toxicity
profile
Presenter: Dr Sara Ghorashian
Session Date and Time: Saturday,
December 7, 2:30 PM Eastern
Time
Title: AUTO1 – Clonal dynamics of
early responder and long-term persisting CAR-T cells in humans
Presenter: Dr Luca Biasco
Session Date and Time: Saturday,
December 7, 8:15 AM Eastern
Time
Title: AUTO3 – Ongoing Phase 1/2
ALEXANDER clinical trial in patients with relapsed/refractory
diffuse large B cell lymphoma (DLBCL)
Presenter: Dr Kirit Ardeshna
Session Date and Time: Saturday,
December 7, 3:15 PM Eastern
Time
The poster presentation details are as
follows:
Title: AUTO2 – Phase 1 First-in-Human study of AUTO2,
the first chimeric antigen receptor (CAR) T cell targeting APRIL
for patients with relapsed/refractory Multiple Myeloma
(RRMM)
Presenter: Dr Rakesh Popat
Session Date and Time: Sunday,
December 8, 6:00 PM –
8:00 PM Eastern Time
Title: AUTO3 – Phase 1/2 AMELIA clinical trial of
AUTO3 in patients with relapsed/refractory pediatric acute
lymphoblastic leukemia (pALL)
Presenter: Professor Persis Amrolia
Session Date and Time: Sunday,
December 8, 6:00 PM –
8:00 PM Eastern Time
About AUTO1
AUTO1 is a CD19 CAR T cell investigational therapy designed to
overcome the limitations in safety - while maintaining similar
levels of efficacy - compared to current CD19 CAR T cell
therapies. Designed to have a fast target binding off-rate to
minimize excessive activation of the programmed T cells, AUTO1 may
reduce toxicity and be less prone to T cell exhaustion, which could
enhance persistence and improve the T cells' abilities to engage in
serial killing of target cancer cells. In 2018, Autolus signed a
license agreement under which Autolus acquired global rights
from UCL Business plc (UCLB), the technology-transfer
company of UCL, to develop and commercialize AUTO1 for the
treatment of B cell malignancies. AUTO1 is currently being
evaluated in two Phase 1 studies, one in pediatric ALL and one in
adult ALL.
About AUTO3
AUTO3 is a programmed T cell therapy containing two independent
chimeric antigen receptors targeting CD19 and CD22 that have each
been independently optimized for single target activity. By
simultaneously targeting two B cell
antigens, AUTO3 is designed to minimize relapse due to single
antigen loss in patients with B cell malignancies. AUTO3 is
currently being tested in pediatric ALL in the AMELIA clinical
trial and in diffuse large B cell lymphoma in the ALEXANDER
clinical trial.
About AUTO2
AUTO2 is the first dual-targeting programmed T cell product
candidate binding to two targets on multiple myeloma cells. AUTO2
uses a human ligand, known as APRIL, which binds to two antigens, B
cell Maturation Antigen, or BCMA, and the transmembrane activator
and CAML interactor, or TACI, both of which are expressed on the
surface of multiple myeloma cancer cells. AUTO2 is designed
to address a key escape route used by hematological cancers in
response to T cell therapies.
About Autolus Therapeutics
plc
Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of
cancer. Using a broad suite of proprietary and modular T cell
programming technologies, the company is engineering precisely
targeted, controlled and highly active T cell therapies that are
designed to better recognize cancer cells, break down their defense
mechanisms and eliminate these cells. Autolus has a pipeline of
product candidates in development for the treatment of
hematological malignancies and solid tumors. For more
information please visit www.autolus.com.
Forward-Looking Statement
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts, and in
some cases can be identified by terms such as "may," "will,"
"could," "expects," "plans," "anticipates," and "believes." These
statements include, but are not limited to, statements regarding
Autolus’ financial condition and results of operations, as well as
statements regarding the anticipated development of Autolus’
product candidates, including its intentions regarding the timing
for providing further updates on the development of its product
candidates, and the sufficiency of its cash resources. Any
forward-looking statements are based on management's current views
and assumptions and involve risks and uncertainties that could
cause actual results, performance or events to differ materially
from those expressed or implied in such statements. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed
on November 23, 2018 as well as
discussions of potential risks, uncertainties, and other important
factors in Autolus' future filings with the Securities and Exchange
Commission from time to time. All information in this press release
is as of the date of the release, and the company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise, except as required by law.
# # #
Investor and media contact:
Silvia Taylor
Vice President, Corporate Affairs and Communications
Autolus
+1-240-801-3850
s.taylor@autolus.com
UK:
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com